Karl Ziegelbauer

Karl Ziegelbauer

UNVERIFIED PROFILE

Are you Karl Ziegelbauer?   Register this Author

Register author
Karl Ziegelbauer

Karl Ziegelbauer

Publications by authors named "Karl Ziegelbauer"

Are you Karl Ziegelbauer?   Register this Author

41Publications

874Reads

-Profile Views

The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.

Exp Dermatol 2014 Aug;23(8):579-84

Department of Dermatology, Venereology and Allergology, University Medical Center, Georg August University, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.12470DOI Listing
August 2014

Product-related research: how research can contribute to successful life-cycle management.

Drug Discov Today 2008 May 20;13(9-10):457-63. Epub 2008 Apr 20.

Bayer HealthCare AG, Global Drug Discovery, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2008.03.001DOI Listing
May 2008

IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.

Mol Cancer Ther 2008 Feb 1;7(2):391-7. Epub 2008 Feb 1.

Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7295, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0305DOI Listing
February 2008

Novel whole-cell antibiotic biosensors for compound discovery.

Appl Environ Microbiol 2007 Oct 24;73(20):6436-43. Epub 2007 Aug 24.

Pharma Research & Development, Discovery Europe, Bayer HealthCare AG, D-42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/AEM.00586-07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075059PMC
October 2007

Genomics: success or failure to deliver drug targets?

Curr Opin Chem Biol 2005 Aug;9(4):387-91

Bayer HealthCare AG, Pharma Research & Development, Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbpa.2005.05.001DOI Listing
August 2005

Strategic alliance management: lessons learned from the Bayer-Millennium collaboration.

Drug Discov Today 2004 Oct;9(20):864-8

Bayer HealthCare AG, 42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1359-6446(04)03250-7DOI Listing
October 2004

Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.

J Biol Chem 2004 Jun 2;279(25):26066-73. Epub 2004 Apr 2.

Institute of Anti-infectives Research, Institute of Chemistry Research, and Institute of Cardiovascular Research, Pharma Research, Bayer HealthCare AG, D-42096 Wuppertal, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M402989200DOI Listing
June 2004

Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones.

J Biol Chem 2003 Oct 15;278(41):39435-42. Epub 2003 Jul 15.

Department of Anti-infectives, Bayer AG, Bayer Health Care, Pharma Research, Aprather Weg 18a, D-42096 Wuppertal, Germany. heike.broetz-oesterhelt.hb@bayer-ag

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M306479200DOI Listing
October 2003

Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors.

Anal Biochem 2003 Apr;315(2):256-61

Research Center Kyoto, Bayer Yakuhin, Ltd, 6-5-1-3, Kunimidai, Kizu-cho, Soraku-gun, Kyoto 619-0216, Japan.

View Article

Download full-text PDF

Source
April 2003